Beyond tolerance, alcohol provides 7 calories per gram with zero nutritional value, directly competes with fat oxidation for metabolic priority, impairs sleep quality, and reduces training performance and recovery
Key Takeaways Tirzepatide vs semaglutide comes down to dual agonist vs single agonist: tirzepatide targets both GLP-1 and GIP receptors, while semaglutide targets GLP-1 alone The only head-to-head trial (SURPASS-2) found tirzepatide superior to semaglutide for both blood sugar control and weight loss In separate obesity trials, tirzepatide 15mg achieved 20.9% weight loss at 72 weeks vs semaglutide 2.4mg's 14.9% at 68 weeks Semaglutide has proven cardiovascular benefit (SELECT trial: 20% MACE reduction)
GLP-1 receptor agonists, such as semaglutide, have emerged as powerful therapeutic agents, transforming the management of type 2 diabetes, weight management, and cardiovascular health
This pricing shift not only expands access but critically opens the door for prevention-focused models that could truly bend the curve on metabolic disease progression across the population
PET data acquisition and reconstruction 11 min after starting the initial bolus infusion of ghrelin/saline, i.e., 1 min after the infusion system switched to slow infusion, 379 62 MBq [11C]raclopride were administered intravenously as a rapid bolus (10 s), and 60-minute dynamic PET data acquisition was started
